Haleon PLC
HLN10.185USD
-0.125-1.21%
Fechamento 04/25, 16:00（ET）Cotações atrasadas em 15 min
92.21BValor de mercado
63.94P/L TTM
Mais detalhes de Haleon PLC Empresa
Haleon plc is a consumer healthcare company. The Company's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.
Informações da empresa
Código da empresaHLN
Nome da EmpresaHaleon PLC
Data de listagemJul 18, 2022
Fundado em2021
CEOMr. Brian Mcnamara
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 18
EndereçoBuilding 5, First Floor
CidadeWEYBRIDGE
Bolsa de valoresLondon Stock Exchange
PaísUnited Kingdom
Código postalKT13 0NY
Telefone441932822000
Sitehttps://www.haleon.com/
Código da empresaHLN
Data de listagemJul 18, 2022
Fundado em2021
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brian Mcnamara
Mr. Brian Mcnamara
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
441.03K
+0.36%
Ms. Lisa Paley
Ms. Lisa Paley
President, North America
President, North America
174.31K
+774.13%
Mr. Jo Russell
Mr. Jo Russell
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Adrian Morris
Mr. Adrian Morris
General Counsel
General Counsel
--
--
Ms. Blathnaid Bergin
Ms. Blathnaid Bergin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ed Petter
Mr. Ed Petter
Chief Corporate Affairs Officer
Chief Corporate Affairs Officer
--
--
Ms. Tracy Clarke
Ms. Tracy Clarke
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Sir Dave Lewis
Sir Dave Lewis
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Keith Choy
Mr. Keith Choy
President, Asia Pacific
President, Asia Pacific
--
--
Mr. Alan J. H. Stewart
Mr. Alan J. H. Stewart
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brian Mcnamara
Mr. Brian Mcnamara
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
441.03K
+0.36%
Ms. Lisa Paley
Ms. Lisa Paley
President, North America
President, North America
174.31K
+774.13%
Mr. Jo Russell
Mr. Jo Russell
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Adrian Morris
Mr. Adrian Morris
General Counsel
General Counsel
--
--
Ms. Blathnaid Bergin
Ms. Blathnaid Bergin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ed Petter
Mr. Ed Petter
Chief Corporate Affairs Officer
Chief Corporate Affairs Officer
--
--
Detalhamento da receita
Moeda: GBPTempo de atualização: dom, 6 de abr
Moeda: GBPTempo de atualização: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaGBP
Nome
Receita
Proporção
Oral health
3.31B
29.48%
Pain relief
2.56B
22.83%
Digestive health and other
1.98B
17.66%
Vitamins, minerals and supplements
1.70B
15.10%
Respiratory health
1.68B
14.93%
Por RegiãoGBP
Nome
Receita
Proporção
Rest of the World
6.25B
55.60%
EMEA and LatAm
4.63B
41.23%
Northern America
4.04B
35.98%
US & Puerto Rico
3.62B
32.19%
APAC
2.56B
22.79%
Other
-9.86B
-87.79%
Por Empresa
Por Região
Por EmpresaGBP
Nome
Receita
Proporção
Oral health
3.31B
29.48%
Pain relief
2.56B
22.83%
Digestive health and other
1.98B
17.66%
Vitamins, minerals and supplements
1.70B
15.10%
Respiratory health
1.68B
14.93%
Acionista
Tempo de atualização: qui, 13 de mar
Tempo de atualização: qui, 13 de mar
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
Dodge & Cox
3.96%
Fidelity Management & Research Company LLC
2.10%
ClearBridge Investments, LLC
0.73%
Harding Loevner LP
0.53%
Wellington Management Company, LLP
0.36%
Other
92.31%
Estatísticas dos acionistas
Acionista
Proporção
Dodge & Cox
3.96%
Fidelity Management & Research Company LLC
2.10%
ClearBridge Investments, LLC
0.73%
Harding Loevner LP
0.53%
Wellington Management Company, LLP
0.36%
Other
92.31%
Tipo
Acionista
Proporção
Investment Advisor/Hedge Fund
5.93%
Investment Advisor
4.89%
Hedge Fund
0.66%
Research Firm
0.40%
Bank and Trust
0.14%
Family Office
0.06%
Family Office
0.06%
Family Office
0.06%
Individual Investor
0.02%
Other
87.79%
Participação acionária institucional
Tempo de atualização: dom, 19 de jan
Tempo de atualização: dom, 19 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
1036
548.64M
12.15%
-206.45M
2024Q4
1094
745.67M
16.47%
-9.34M
2024Q3
1096
717.29M
15.74%
-81.04M
2024Q2
1078
719.27M
15.75%
-155.43M
2024Q1
1041
707.36M
15.49%
-53.58M
2023Q4
993
691.96M
14.98%
-58.05M
2023Q3
933
688.70M
14.92%
-37.88M
2023Q2
891
677.74M
14.68%
-44.11M
2023Q1
842
667.68M
14.46%
-14.30M
2022Q4
781
634.24M
13.73%
+23.14M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Dodge & Cox
178.74M
3.96%
-427.46K
-0.24%
Dec 31, 2024
Fidelity Management & Research Company LLC
94.69M
2.1%
+3.67M
+4.04%
Dec 31, 2024
ClearBridge Investments, LLC
32.80M
0.73%
-4.57M
-12.22%
Dec 31, 2024
Harding Loevner LP
24.13M
0.53%
-761.67K
-3.06%
Dec 31, 2024
Wellington Management Company, LLP
16.41M
0.36%
+1.08M
+7.04%
Mar 19, 2025
Fidelity Institutional Asset Management
14.14M
0.31%
+236.08K
+1.70%
Dec 31, 2024
Sculptor Capital Management, Inc
8.89M
0.2%
--
--
Dec 31, 2024
Aristotle Capital Management, LLC
8.75M
0.19%
-239.48K
-2.66%
Dec 31, 2024
Douglas C. Lane & Associates
8.62M
0.19%
+161.87K
+1.91%
Dec 31, 2024
Envestnet Asset Management, Inc.
7.63M
0.17%
+58.44K
+0.77%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
VanEck Pharmaceutical ETF
4.76%
ClearBridge Dividend Strategy ESG ETF
2.1%
Fidelity Blue Chip Value ETF
0.92%
SP Funds S&P World (ex-US) ETF
0.37%
ActivePassive International Equity ETF
0.36%
Pacer Trendpilot International ETF
0.23%
Avantis International Equity ETF
0.12%
Avantis Responsible International Equity ETF
0.11%
Avantis International Large Cap Value ETF
0%
Knowledge Leaders Developed World ETF
0%
Ver Mais
VanEck Pharmaceutical ETF
Proporção4.76%
ClearBridge Dividend Strategy ESG ETF
Proporção2.1%
Fidelity Blue Chip Value ETF
Proporção0.92%
SP Funds S&P World (ex-US) ETF
Proporção0.37%
ActivePassive International Equity ETF
Proporção0.36%
Pacer Trendpilot International ETF
Proporção0.23%
Avantis International Equity ETF
Proporção0.12%
Avantis Responsible International Equity ETF
Proporção0.11%
Avantis International Large Cap Value ETF
Proporção0%
Knowledge Leaders Developed World ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Aug 01, 2024
HLN.NB Final Cash Dividend of gross USD 0.051416 paid on Sep 19, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 19, 2024
Aug 16, 2024
Feb 29, 2024
HLN.NB Interim Cash Dividend of gross USD 0.105268 paid on May 16, 2024 going ex on Mar 14, 2024
Mar 15, 2024
May 16, 2024
Mar 14, 2024
Aug 02, 2023
HLN.NB Final Cash Dividend of gross USD 0.043871 paid on Oct 05, 2023 going ex on Aug 24, 2023
Aug 25, 2023
Oct 05, 2023
Aug 24, 2023
Mar 02, 2023
HLN.NB Interim Cash Dividend of gross USD 0.059732 paid on Apr 27, 2023 going ex on Mar 16, 2023
Mar 17, 2023
Apr 27, 2023
Mar 16, 2023
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados